Meeting
2024 ASCO Annual Meeting
Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.
Authors
Ines Esteves Domingues Pires Da Silva
Melanoma Institute Australia, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, and Blacktown Hospital, Sydney, NSW, Australia
Ines Esteves Domingues Pires Da Silva , Jordan W. Conway , Akshaya Ramanathan , Laura Smith , Robert V Rawson , Piyush Grover , Nigel Maher , Jorja Braden , Maria Gonzalez , Umaimainthan Palendira , Alexander M. Menzies , Richard A Scolyer , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT04207086
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9566)
DOI
10.1200/JCO.2024.42.16_suppl.9566
Abstract #
9566
Poster Bd #
350
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.
First Author: Maria Gonzalez
Poster
2023 ASCO Annual Meeting
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
First Author: Milton Jose De Barros E Silva
Poster
2023 ASCO Annual Meeting
The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.
First Author: Irene L.M. Reijers
Poster
2023 ASCO Annual Meeting
NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
First Author: Lili Mao